Peritoneal mesothelioma  

作　　者：Yutaka Yonemura Haruaki Ishibashi Akiyoshi Mizumoto Takuji Fujita Yang Liu Satoshi Wakama Syouzou Sako Nobuyuki Takao Toshiyuki Kitai Kanji Katayama Yasuyuki Kamada Keizou Taniguchi Daisuke Fujimoto 

机构地区：[1]Asian School of Peritoneal Surface Malignancy Treatment,Kyoto City,Kyoto 600-8189 Japan [2]Department of Regional Cancer Therapy,Peritoneal Dissemination Center,Kishiwada Tokushukai Hospital,Kishiwada City,Oosaka 596-8522 Japan [3]Department of Regional Cancer Therapy,Peritoneal Dissemination Center,Kusatsu General Hospital,Kusatsu City,Shiga 525-8585 Japan [4]Department of Surgery,Mizonokuchi Hospital,Teikyo University,School of Medicine,Kawasaki,Kanagawa 213-8507,Japan

出　　处：《Journal of Cancer Metastasis and Treatment》2022年第1期114-125,共12页癌症转移与治疗（英文版）

摘　　要：This review provides an overview of articles about peritoneal mesothelioma(PM)to analyze the effect of treatment modalities on response rates,post-treatment side effects,morbidity and mortality,and survival.Median survival in months following systemic chemotherapy(SC)ranged from 8.7 to 26.8 months.However,no patient was reported to have survived for more than five years with SC alone.In contrast,comprehensive treatment that included cytoreductive surgery(CRS)+perioperative chemotherapy(POC)showed a significantly longer median survival time than SC alone.Additionally,CRS+POC demonstrated 10-year survival rates of 12%-35%.Accordingly,CRS+POC is an innovative treatment that provides long-term survival in selected patients with PM.Selection criteria are performance status(ECOG PS≤1),the absence of extraperitoneal metastasis,PCI less than cutoff levels(from<10 to<28),MIB-1 index(<10),and histologic type(epithelioid type).Postoperative morbidity and mortality rates after CRS+POC were significantly higher than with more conventional operations.Accordingly,CRS and POC should be done at the specialized peritoneal surface malignancy centers.

关 键 词：Peritoneal mesothelioma MESOTHELIOMA intraperitoneal chemotherapy HIPEC PERITONECTOMY 

分 类 号：R735.5[医药卫生—肿瘤]